Literature DB >> 31138774

Trends in isolated aortic valve replacement in middle‑aged patients over the last 10 years: epidemiology, risk factors, valve pathology, valve types, and outcomes.

Grzegorz Filip1, Radosław Litwinowicz1, Bogusław Kapelak1, Jerzy Sadowski1, Zdzisław Tobota2, Bohdan Maruszewski2, Krzysztof Bartuś1.   

Abstract

BACKGROUND: Valve prosthesis selection in aortic valve replacement (AVR) is particularly difficult in middle‑aged patients (60-70 years old). AIMS: We described changes in trends and outcomes of AVR in middle‑aged patients over the last 10 years, based on the real‑life single‑center data from the Polish National Registry.
METHODS: A total of 4912 consecutive adult patients who underwent any type of isolated aortic valve surgery between 2006 to 2016 were included. The main outcome measures were changes in the number of procedures, characteristics, surgical details, and in‑hospital mortality.
RESULTS: Out of all 4912 AVR procedures performed, 1531 patients (31.2%) were between 60 and 70 years of age. The share of aortic valve prosthesis in the overall number of replacements changed between 2006 and 2016 for mechanical valves (MV) from 98.3% to 15.2% and for biological valves (BV) from 0% to 81.8% (P <0.001 for both comparisons). In the BV group, stented valves were implanted in 92.6%. The most common MV was the St. Jude Medical Mechanical Heart Valve (St. Jude Medical, Saint Paul, Minnesota, United States) and most common BV was the Carpentier‑Edwards Perimount Magna (Edwards Lifesciences, Irvine, California, United States). The most common prosthesis size was 23 mm. There were no significant differences in body mass index and comorbidities between the patients with MV and BV. The overall in‑hospital mortality was 3.46% (3.33% in the MV group and 3.69% in the BV group; P = 0.85).
CONCLUSIONS: In the last 10 years, one‑third of aortic valve replacements were performed in patients between 60 and 70 years of age. We observed rapidly changing trends in the type of implanted valve prostheses.

Entities:  

Mesh:

Year:  2019        PMID: 31138774     DOI: 10.33963/KP.14854

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  5 in total

1.  Decrease of surgical heart disease treatment during the COVID-19 pandemic (Cardiac Surgery COVID-19 Study - CSC 19 Study).

Authors:  Radoslaw Litwinowicz; Grzegorz Filip; Boguslaw Kapelak; Magdalena Bryndza; Kazimierz Widenka; Marek Deja; Piotr Suwalski; Mariusz Kowalewski; Krzysztof Bartus
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-06-29

2.  Bioprosthetic or mechanical heart valves: prosthesis choice for borderline patients?-Results from 9,616 cases recorded in Polish national cardiac surgery registry.

Authors:  Krzysztof Bartus; Radosław Litwinowicz; Jerzy Sadowski; Grzegorz Filip; Mariusz Kowalewski; Piotr Suwalski; Piotr Mazur; Anna Kędziora; Marek Jasiński; Marek Deja; Mariusz Kuśmierczyk; Pawel Czub; Michal Zembala; Marek Jemielity; Rafał Pawlaczyk; Zdzisław Tobota; Bohdan Maruszewski; Boguslaw Kapelak
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

3.  Early experience with the Thopaz+ chest drainage system - is this a new era in the management of post-cardiotomy bleeding?

Authors:  Karolina Pawelkowska; Stanislaw Bartus; Robert Sobczynski; Michal Medrzycki; Grzegorz Grudzien; Grzegorz Filip; Bartosz Cierpikowski; Krzysztof Bartus; Boguslaw Kapelak
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-01-09

4.  Long-term survival following postoperative myocardial infraction after coronary artery bypass surgery.

Authors:  Radosław Litwinowicz; Piotr Mazur; Piotr Śliwiński; Magdalena Bryndza; Krzysztof Bartuś; Grzegorz Filip; Artur Bartoszcze; Jacek Piątek; Janusz Konstanty-Kalandyk; Mariusz Kowalewski; Krithika Ramaprabhu; Hubert Hymczak; Bogusław Kapelak; Anna Kędziora
Journal:  J Thorac Dis       Date:  2022-01       Impact factor: 3.005

5.  Quality of life in sexagenarians after aortic biological vs mechanical valve replacement: a single-center study in China.

Authors:  Li-Wen Wang; Ning Xu; Shu-Ting Huang; Liang-Wan Chen; Hua Cao; Qiang Chen
Journal:  J Cardiothorac Surg       Date:  2020-05-12       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.